Union Funds Exit Amgen, Teva Antitrust MDL

By Nadia Dreid · January 10, 2024, 10:18 PM EST

Teva Pharmaceuticals has settled its differences with the union funds making up the indirect purchase class in multidistrict litigation accusing it of hatching an illegal deal to remove a generic calcium-control...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Motion

Case Information

Case Title

In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation

Case Number

Court

Delaware

Nature of Suit

Anti-Trust

Date Filed

July 31, 2019

Recent Articles By Nadia

July 17, 2024
Teladoc Hit With Another Investor Suit Over BetterHelp Woes
July 11, 2024
Pfizer's $50M EpiPen Deal Gets Final OK In Antitrust Suit
June 27, 2024
Judge OKs $10M Deal In Generic Price-Fixing MDL
April 16, 2024
NC Treasurer Backs FTC On Hospital Merger Challenge
April 09, 2024
White House, Senate Dems Want $1.3B To Fight COVID Fraud
March 01, 2024
NY Judge Tosses $6.4B BMS Investor Action For Good
February 21, 2024
39 AGs Call For Federal Pharmacy Benefit Manager Reform
February 05, 2024
States Ask Justices To End Feds' Alleged Online Censorship
December 07, 2023
Ariz. BCBS Rips 'Kitchen-Sink' Suit Over Low Doctor Payouts
November 20, 2023
Invisalign Antitrust Classes Win Some, Lose Some On Cert.